CLARINEX
LOE ApproachingNDAORALSOLUTION
Approved
Sep 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CLARINEX by Merck & Co. is 1 -receptor histamine antagonist activity. First approved in 2004.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLARINEX (desloratadine) is an oral H1-receptor antagonist antihistamine used to treat allergic rhinitis and urticaria by blocking histamine release from mast cells. The formulation also contains pseudoephedrine sulfate, a sympathomimetic decongestant that reduces nasal congestion. It does not significantly cross the blood-brain barrier, minimizing sedation compared to first-generation antihistamines.
$0.289MPart D
LOE ApproachingProduct approaching loss of exclusivity with minimal Part D volume signals a contracting brand team and reduced commercial headcount.
Mechanism of Action
1 -receptor histamine antagonist activity. Receptor binding data indicate that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CLARINEX offers minimal career development opportunity as a mature, genericized product with no linked job openings in the current market. Career growth is constrained to defensive account management and legacy brand maintenance with limited advancement potential.
Worked on CLARINEX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.